2023 World Conference on Lung Cancer (Posters)-EP11.02. Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer

EP11.02. Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

A study was conducted to evaluate the efficacy and safety of the combination of camrelizumab and famitinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). The study included patients who had progressed after first-line chemotherapy and had either EGFR mutations or had progressed after immunotherapy. The primary endpoint of the study was the objective response rate (ORR) using RECIST v1.1 criteria. <br /><br />A total of 23 patients were enrolled in the study and received camrelizumab plus famitinib. The median age of the patients was 63 years and 65.2% were male. Most patients had stage IV disease and 21.7% had brain metastasis. Six patients had EGFR mutations. The median line of previous treatment was 1. <br /><br />The unconfirmed ORR was 39.1%, while the confirmed ORR was 30.4%. The disease control rate (DCR) was 95.7%. For patients without EGFR mutations, the confirmed ORR was 29.4%, while for those with EGFR mutations, the confirmed ORR was 33.3%. The median progression-free survival (PFS) was 6.9 months. <br /><br />The most common grade 3 or above treatment-related adverse events (TRAEs) included decreased platelet count, decreased white blood cell count, hypertension, proteinuria, hypertriglyceridemia, decreased lymphocyte count, and increased alanine aminotransferase. No unexpected adverse events were reported. <br /><br />In conclusion, the combination of camrelizumab and famitinib demonstrated promising clinical activity with a manageable safety profile in previously treated patients with advanced NSCLC. Further validation of these results is needed.

Asset Subtitle

Ming Gao

Meta Tag

Speaker Ming Gao

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

efficacy

safety

combination

camrelizumab

famitinib

NSCLC

chemotherapy

EGFR mutations

ORR

adverse events